{
  "main_header": {
    "sid": 116063,
    "name": "Samrat Pharma",
    "stock_name": "Samrat Pharma",
    "full_name": "Samrat Pharmachem Ltd",
    "name_url": "stocks-analysis/samrat-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "336.00",
    "chg": 16,
    "chgp": "5.0%",
    "dir": 1,
    "prev_price": "320.00",
    "mcapval": "103.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530125,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE103E01016",
    "curr_date": "Apr 11, 12:48 PM",
    "curr_time": "01:14 AM",
    "bse_nse_vol": "3.33 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/samrat-pharma-116063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Samrat Pharmachem Adjusts Evaluation Amid Strong Management Efficiency and Debt Servicing Capability",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-receives-hold-rating-as-stock-price-rises-to-322-30-1670600",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/4/SamratPharmache_mojoScore_861548.png",
        "date": "2025-04-02 08:06:24",
        "description": "Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has recently seen a change in its evaluation. The company exhibits strong management efficiency with a 27.61% return on capital employed and a low debt-to-EBITDA ratio of 0.44. However, it has underperformed against benchmark indices over the past three years."
      },
      {
        "title": "Samrat Pharmachem Faces Challenges Despite Strong Management Efficiency and Attractive Valuation",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-hits-52-week-low-amid-broader-market-decline-and-small-cap-gains-1641127",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/SamratPharmache_priceRelatedfactors_834373.png",
        "date": "2025-03-28 10:35:32",
        "description": "Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has recently hit a 52-week low and experienced a decline over the past four days. Despite strong management efficiency and positive quarterly results, its long-term growth appears limited, and it has underperformed against benchmark indices."
      },
      {
        "title": "Samrat Pharmachem Hits 52-Week Low Amid Broader Market Recovery Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-hits-52-week-low-amid-sector-underperformance-and-declining-stock-price-1554700",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/SamratPharmache_priceRelatedfactors_767085.png",
        "date": "2025-03-21 15:05:14",
        "description": "Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, reflecting a decline despite recent gains. The company's performance has lagged behind the broader market, with a year-over-year drop, although it maintains strong management efficiency and consistent quarterly profit growth."
      },
      {
        "title": "Samrat Pharmachem Hits 52-Week Low Amidst Sector Underperformance and Bearish Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-hits-52-week-low-amid-broader-market-decline-and-sector-underperformance-1272727",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/SamratPharmache_priceRelatedfactors_638943.png",
        "date": "2025-03-11 11:35:13",
        "description": "Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, underperforming its industry. The stock has declined over the past two days and is trading below key moving averages. However, the company demonstrates strong management efficiency and consistent positive financial results."
      },
      {
        "title": "Samrat Pharmachem Adjusts Valuation Grade Amid Competitive Pharmaceuticals Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachems-valuation-grade-upgraded-from-attractive-to-very-attractive-1228645",
        "imagepath": "",
        "date": "2025-03-07 08:00:33",
        "description": "Samrat Pharmachem has recently undergone a valuation adjustment, reflecting a notable shift in its financial standing within the pharmaceuticals and drugs industry. The company's current price stands at 344.10, with a 52-week range between 320.00 and 646.00. Key financial metrics indicate a PE ratio of 11.93 and an EV to EBITDA ratio of 9.17, suggesting a competitive position in the market.\n\nThe company's return metrics show a mixed performance compared to the Sensex. Over the past year, Samrat Pharmachem has experienced a decline of 3.59%, while the Sensex has seen a slight increase of 0.34%. However, over a five-year period, the company has delivered a substantial return of 416.67%, significantly outperforming the Sensex's 97.84%.\n\nIn comparison to its peers, Samrat Pharmachem's valuation metrics, such as its low PE ratio and favorable EV to EBIT ratio, position it favorably against companies like Shree G..."
      },
      {
        "title": "Samrat Pharmachem Reports Strong Profit Growth Amid Declining Net Sales in February 2025",
        "link": "https://www.marketsmojo.com/news/result-analysis/samrat-pharmachem-reports-highest-operating-profit-of-rs-4-17-crore-in-december-2024-1014119",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/SamratPharmache_quaterlyResult_450436.png",
        "date": "2025-02-14 18:45:34",
        "description": "Samrat Pharmachem has announced its financial results for the quarter ending December 2024, showcasing significant growth in operating profit and profit margins. The company reported its highest operating profit at Rs 4.17 crore and an EPS of Rs 9.00, despite a decline in net sales to Rs 63.66 crore."
      }
    ],
    "total": 3761,
    "sid": "116063",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/samrat-pharmachem-116063"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Notice Of Board Meeting For Approval Of Audited Financial Results For The Financial Year Ended March 31 2025",
      "datetime": "26-Mar-2025",
      "details": "Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve the Audited Standalone Financial Results of the Company for the financial year ended March 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "20-Mar-2025",
      "details": "The trading window of the company shall remain closed from Tuesday April 1 2025 till 48 hours after the declaration of the Audited Financial Results of the company for the year ended March 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Integrated Filing (Financial)",
      "datetime": "04-Mar-2025",
      "details": "Integrated Filing (Financial) for the quarter and nine months ended December 31 2024",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "30 May 2025"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Samrat Pharmachem Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 24",
          "dt": "2024-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Samrat Pharmachem Adjusts Evaluation Amid Strong Management Efficiency and Debt Servicing Capability

2025-04-02 08:06:24

Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has recently seen a change in its evaluation. The company exhibits strong management efficiency with a 27.61% return on capital employed and a low debt-to-EBITDA ratio of 0.44. However, it has underperformed against benchmark indices over the past three years.

Read More

Samrat Pharmachem Faces Challenges Despite Strong Management Efficiency and Attractive Valuation

2025-03-28 10:35:32

Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has recently hit a 52-week low and experienced a decline over the past four days. Despite strong management efficiency and positive quarterly results, its long-term growth appears limited, and it has underperformed against benchmark indices.

Read More

Samrat Pharmachem Hits 52-Week Low Amid Broader Market Recovery Trends

2025-03-21 15:05:14

Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, reflecting a decline despite recent gains. The company's performance has lagged behind the broader market, with a year-over-year drop, although it maintains strong management efficiency and consistent quarterly profit growth.

Read More

Samrat Pharmachem Hits 52-Week Low Amidst Sector Underperformance and Bearish Trends

2025-03-11 11:35:13

Samrat Pharmachem, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, underperforming its industry. The stock has declined over the past two days and is trading below key moving averages. However, the company demonstrates strong management efficiency and consistent positive financial results.

Read More

Samrat Pharmachem Adjusts Valuation Grade Amid Competitive Pharmaceuticals Landscape

2025-03-07 08:00:33

Samrat Pharmachem has recently undergone a valuation adjustment, reflecting a notable shift in its financial standing within the pharmaceuticals and drugs industry. The company's current price stands at 344.10, with a 52-week range between 320.00 and 646.00. Key financial metrics indicate a PE ratio of 11.93 and an EV to EBITDA ratio of 9.17, suggesting a competitive position in the market. The company's return metrics show a mixed performance compared to the Sensex. Over the past year, Samrat Pharmachem has experienced a decline of 3.59%, while the Sensex has seen a slight increase of 0.34%. However, over a five-year period, the company has delivered a substantial return of 416.67%, significantly outperforming the Sensex's 97.84%. In comparison to its peers, Samrat Pharmachem's valuation metrics, such as its low PE ratio and favorable EV to EBIT ratio, position it favorably against companies like Shree G...

Read More

Samrat Pharmachem Reports Strong Profit Growth Amid Declining Net Sales in February 2025

2025-02-14 18:45:34

Samrat Pharmachem has announced its financial results for the quarter ending December 2024, showcasing significant growth in operating profit and profit margins. The company reported its highest operating profit at Rs 4.17 crore and an EPS of Rs 9.00, despite a decline in net sales to Rs 63.66 crore.

Read More

View All News